Man Group plc Acquires New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Man Group plc acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 70,802 shares of the company's stock, valued at approximately $479,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $27,000. Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 220.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock worth $66,000 after purchasing an additional 6,758 shares in the last quarter. Finally, Colonial River Investments LLC bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $68,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Up 1.4%

NASDAQ:RXRX traded up $0.06 on Thursday, hitting $4.45. The stock had a trading volume of 21,617,503 shares, compared to its average volume of 13,579,664. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market cap of $1.81 billion, a P/E ratio of -2.91 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The firm's fifty day simple moving average is $5.00 and its two-hundred day simple moving average is $6.45.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same quarter last year, the business posted ($0.39) EPS. The company's quarterly revenue was up 7.2% on a year-over-year basis. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of analyst reports. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Morgan Stanley lowered their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.